



January 13, 2014

TG Therapeutics, Inc. to Present at the 32nd Annual J.P. Morgan Healthcare Conference

Presentation Scheduled for Thursday, January 16th at 1:00 PM PST

NEW YORK, Jan. 13, 2014 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX) today announced that Michael Weiss, the Company's Interim Chief Executive Officer, will be presenting at the 32nd Annual J.P. Morgan Healthcare Conference, being held at the Westin St. Francis Hotel in San Francisco. Mr. Weiss will discuss updates on the Company's two lead compounds for hematologic malignancies; TG-1101 (ublituximab) and TGR-1202. The presentation is scheduled to take place on Thursday, January 16, 2014 at 1:00 PM PST. A live webcast of this presentation will be available on the Events page of the Company's website at www.tgtherapeutics.com.

ABOUT TG THERAPEUTICS, INC.

TG Therapeutics is an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently, the company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. TG Therapeutics is headquartered in New York City.

TGTX - G

CONTACT: Jenna Bosco

Director- Investor Relations

TG Therapeutics, Inc.

Telephone: 212.554.4484

Email: ir@tgtxinc.com



Source: TG Therapeutics, Inc.

News Provided by Acquire Media